Montanova Capital, LLC holds a diversified book of 88 stocks worth $3.7B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Veradermics Inc and trimmed Apellis Pharmaceuticals Inc. Their largest long position is Arcutis Biotherapeutics Inc at 8% of the equity book. They also disclosed $227.6M in put options (a bearish bet), shown separately below and excluded from the equity book.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
95% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Montanova Capital, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 80 / 80 | $255.0B |
| UBS Group AG | 79 / 80 | $66.8B |
| JPMORGAN CHASE & CO | 78 / 80 | $286.7B |
| MILLENNIUM MANAGEMENT LLC | 77 / 80 | $11.2B |
| BANK OF AMERICA CORP /DE/ | 76 / 80 | $142.8B |
| BARCLAYS PLC | 76 / 80 | $54.6B |
| CITIGROUP INC | 76 / 80 | $31.0B |
| BNP PARIBAS FINANCIAL MARKETS | 76 / 80 | $26.8B |
Ranked by how many of Montanova Capital, LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Arcutis Biotherapeutics Inc COM | $290.4M | 12.33M | 7.9% | ▲+3.0% Added · +363K sh | |
| 2 | Veradermics Inc COMMON STOCK | $263.3M | 4.17M | 7.1% | ▲New New position | |
| 3 | Palvella Therapeutics Inc Ne COM | $143.8M | 1.15M | 3.9% | ▲+29% Added · +261K sh | |
| 4 | Apellis Pharmaceuticals Inc COM | $141.5M | 3.52M | 3.8% | ▼−15% Reduced · −621K sh | |
| 5 | Legend Biotech Corp SPONSORED ADS | $137.1M | 7.58M | 3.7% | ▲+15% Added · +972K sh | |
| 6 | Benitec Biopharma Inc COM NEW | $123.0M | 11.55M | 3.3% | —Held | |
| 7 | Capricor Therapeutics Inc COM NEW | $116.1M | 3.82M | 3.1% | ▲+114% Added · +2.0M sh | |
| 8 | Immatics N.V SHS | $110.1M | 11.19M | 3.0% | —Held | |
| 9 | Arcus Biosciences Inc COM | $108.7M | 5.03M | 2.9% | ▼−3.0% Reduced · −158K sh | |
| 10 | Eyepoint Inc COM NEW | $106.9M | 8.30M | 2.9% | ▲+6.0% Added · +469K sh | |
| 11 | Arrivent Biopharma Inc COM | $101.5M | 4.40M | 2.8% | ▲+7.2% Added · +295K sh | |
| 12 | Taiwan Semiconductor Manufac SPONSORED ADS | $100.9M | 298.7K | 2.7% | ▲+10% Added · +27K sh | |
| 13 | Nvidia Corporation COM | $100.2M | 574.7K | 2.7% | ▲+8.2% Added · +44K sh | |
| 14 | Meta Platforms Inc CL A | $97.1M | 169.7K | 2.6% | ▲+0.4% Added · +638 sh | |
| 15 | Kalvista Pharmaceuticals Inc COM | $96.0M | 4.77M | 2.6% | —Held | |
| 16 | Ge Aerospace COM NEW | $88.0M | 310.3K | 2.4% | —Held | |
| 17 | Biohaven Ltd COM | $87.0M | 10.29M | 2.4% | —Held | |
| 18 | Sysco Corp COM | $82.7M | 1.16M | 2.2% | ▲+7.0% Added · +75K sh | |
| 19 | MGM Resorts International COM | $79.9M | 2.16M | 2.2% | ▲+80% Added · +957K sh | |
| 20 | Compass Therapeutics Inc COM | $75.7M | 14.31M | 2.1% | ▲+0.9% Added · +125K sh | |
| 21 | Home Depot Inc COM | $72.9M | 221.6K | 2.0% | ▼−8.0% Reduced · −19K sh | |
| 22 | Kura Oncology Inc COM | $69.7M | 8.58M | 1.9% | —Held | |
| 23 | Monte Rosa Therapeutics Inc COM | $69.5M | 4.23M | 1.9% | ▲+26% Added · +867K sh | |
| 24 | Bank America Corp COM | $63.1M | 1.30M | 1.7% | ▼−15% Reduced · −222K sh | |
| 25 | Erasca Inc COM | $55.6M | 3.43M | 1.5% | ▼−76% Reduced · −11.1M sh | |
| 26 | Capital One Finl Corp COM | $55.2M | 302.4K | 1.5% | ▲+76% Added · +130K sh | |
| 27 | Zura Bio Ltd CLASS A ORD SHS | $53.9M | 9.07M | 1.5% | ▲+63% Added · +3.5M sh | |
| 28 | Amazon Com Inc COM | $52.9M | 254.0K | 1.4% | ▼−37% Reduced · −152K sh | |
| 29 | Advanced Micro Devices Inc COM | $52.3M | 257.2K | 1.4% | ▼−34% Reduced · −132K sh | |
| 30 | Fulcrum Therapeutics Inc COM | $50.3M | 6.56M | 1.4% | —Held | |
| 31 | Vulcan Matls Co COM | $49.4M | 181.6K | 1.3% | ▲New New position | |
| 32 | Ferguson Enterprises Inc COMMON STOCK NEW | $49.4M | 211.9K | 1.3% | ▲+33% Added · +53K sh | |
| 33 | Apollo Global Mgmt Inc COM | $43.2M | 387.7K | 1.2% | ▼−29% Reduced · −155K sh | |
| 34 | Mineralys Therapeutics Inc COM | $41.7M | 1.54M | 1.1% | —Held | |
| 35 | Crinetics Pharmaceuticals In COM | $37.9M | 1.04M | 1.0% | ▲New New position | |
| 36 | Contineum Therapeutics Inc CL A | $37.1M | 2.84M | 1.0% | —Held | |
| 37 | US Foods Hldg Corp COM | $36.5M | 396.0K | 1.0% | ▲New New position | |
| 38 | Performance Food Group Co COM | $33.1M | 386.9K | 0.9% | ▲New New position | |
| 39 | Replimune Group Inc COM | $32.3M | 4.22M | 0.9% | ▲117× Added · +4.2M sh | |
| 40 | Advisorshares TR PURE US CANNABIS | $32.1M | 9.05M | 0.9% | ▲+4.3% Added · +377K sh | |
| 41 | Aura Biosciences Inc COM | $29.3M | 4.37M | 0.8% | —Held | |
| 42 | Unitedhealth Group Inc COM | $27.2M | 100.6K | 0.7% | ▼−9.6% Reduced · −11K sh | |
| 43 | Prokidney Corp SHS CL A | $22.1M | 12.34M | 0.6% | —Held | |
| 44 | Life Time Group Holdings Inc COMMON STOCK | $13.7M | 510.3K | 0.4% | ▲New New position | |
| 45 | Whitehawk Therapeutics Inc COM | $12.8M | 3.70M | 0.3% | —Held | |
| 46 | Abeona Therapeutics Inc COM NEW | $12.0M | 2.68M | 0.3% | —Held | |
| 47 | Wingstop Inc COM | $9.2M | 59.5K | 0.3% | ▲New New position | |
| 48 | Molecular Partners AG ADS | $8.8M | 2.22M | 0.2% | —Held | |
| 49 | Boston Scientific Corp COM | $7.8M | 123.9K | 0.2% | ▼−65% Reduced · −230K sh | |
| 50 | Lexeo Therapeutics Inc COM | $7.2M | 1.25M | 0.2% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1569064/holdings"
Use Arkolith to show MONTANOVA CAPITAL, LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $227.6M | 350K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 89 | $3.9B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 93 | $4.9B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 93 | $3.9B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 98 | $3.3B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 100 | $2.7B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 96 | $2.9B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 98 | $3.1B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 98 | $2.7B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 101 | $2.7B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 88 | $2.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 87 | $1.9B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 100 | $1.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 95 | $2.4B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 89 | $2.4B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 73 | $2.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 89 | $2.6B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 87 | $3.3B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 95 | $5.2B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 16, 2021 | 106 | $5.9B | 13F-HR/A |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 122 | $6.7B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 106 | $6.8B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 106 | $7.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.